發明
中華民國
110115917
I 786619
抑制SCUBE2,一新穎VEGFR2輔受體,遏止腫瘤血管新生
中央研究院
2022/12/11
本發明涉及使用至少一種能專一性結合於人類與鼠血管內皮細胞SCUBE2之單株抗體或其片段。於哺乳動物宿主施打有效劑量之SCUBE2單株抗體或其片段能有效達到抗血管新生之治療效果,此SCUBE2單株抗體或其片段同時具有血管新生抑制劑與抗腫瘤 製劑之特性。本專利不但可應用於治療腫瘤與血管新生相關疾病,於新生血管型眼部病變上也具開發價值。 The present invention relates to the use of at least one anti-SCUBE2 monoclonal antibody, or fragments thereof, having binding specificity for both SCUBE2 expressed on human vascular endothelial cells and on murine endothelial cells. Anti-angiogenic therapy in mammals can be effected by administering to the mammalian host a therapeutically effective amount of an anti-SCUBE2 monoclonal antibody, or fragments thereof, which is conjugated to at least one angiogenesis inhibitor or antitumor agent. The composition is useful for treating tumors and angiogenesis-associated diseases such as, but not limited to, neovascular eye disorders.
智財技轉處
02-2787-2508
版權所有 © 國家科學及技術委員會 National Science and Technology Council All Rights Reserved.
建議使用IE 11或以上版本瀏覽器,最佳瀏覽解析度為1024x768以上|政府網站資料開放宣告
主辦單位:國家科學及技術委員會 執行單位:台灣經濟研究院 網站維護:台灣經濟研究院